Probenesid ve kolşisin etkileşimleri

Co-administration with probenecid is not recommended. (Amoksisilin ve klavulanat etiketi, İlaç etkileşimleri)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

Antigout: colchicine ↑ colchicine The coadministration of REYATAZ with colchicine in patients with renal or hepatic impairment is not recommended. (Atazanavir etiketi, İlaç etkileşimleri)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

Thus, probenecid should not be administered concurrently with bumetanide. (Bumetanid etiketi, İlaç etkileşimleri)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product: St. (Darunavir etiketi, Kontrendikasyonlar)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine… (Darunavir ve kobisistat etiketi, Kontrendikasyonlar)

Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (Deferipron etiketi, İlaç etkileşimleri)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

Anti-gout: colchicine ↑ colchicine GENVOYA is not recommended to be coadministered with colchicine to patients with renal or hepatic impairment. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended. (Ertapenem etiketi, İlaç etkileşimleri)

Therefore, it is not recommended that probenecid be given concomitantly with PRIMAXIN. (İmipenem ve silastatin etiketi, İlaç etkileşimleri)

Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment. (İtrakonazol etiketi, Kutulu uyarı)

…contraindicated with ketoconazole tablets: methadone, disopyramide, dronedarone, ergot alkaloids such as dihydroergotamine, ergometrine, ergotamine, methylergometrine, irinotecan, lurasidone, oral midazolam, alprazolam, triazolam, felodipine, nisoldipine, ranolazine, tolvaptan, eplerenone, lovastatin, simvastatin and colchicine (see PRECAUTIONS: Drug Interactions ). (Ketokonazol etiketi, Kontrendikasyonlar)

Therefore, the combination of ketoprofen and probenecid is not recommended. (Ketoprofen etiketi, Uyarılar ve önlemler)

The concomitant use of ketorolac tromethamine and probenecid is contraindicated. (Ketorolak etiketi, Kontrendikasyonlar)

Colchicine in renal or hepatic impairment ( 4.4 ) (Klaritromisin etiketi, Kontrendikasyonlar)

Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin… (Lopinavir ve ritonavir etiketi, Kontrendikasyonlar)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

Co-administration of Meropenem for injection with probenecid inhibits renal excretion of meropenem and is therefore not recommended ( 7.1 ) (Meropenem etiketi, İlaç etkileşimleri)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

…Interactions (7.3) ] : • Alpha 1-adrenoreceptor antagonist: alfuzosin • Antianginal: ranolazine • Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine • Anti-gout: colchicine (in patients with renal and/or hepatic impairment [see Table 2 , Drug Interactions (7.3)] ) • Antipsychotics: lurasidone, pimozide • Benign prostatic hyperplasia agents:… (Nirmatrelvir ve ritonavir etiketi, Kontrendikasyonlar)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (Piperasilin ve tazobaktam etiketi, İlaç etkileşimleri)

Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (Pralatreksat etiketi, İlaç etkileşimleri)

…Adrenoreceptor Antagonist: alfuzosin ○ Antianginal: ranolazine ○ Antiarrhythmics: amiodarone, dronedarone, flecainide, propafenone, quinidine ○ Antifungal: voriconazole ○ Anti-gout: colchicine ○ Antipsychotics: lurasidone, pimozide ○ Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine ○ GI Motility Agent: cisapride ○ HMG-CoA Reductase Inhibitors:… (Ritonavir etiketi, Kontrendikasyonlar)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

Co-administration of probenecid with cephalexin for oral suspension is not recommended. (Sefaleksin etiketi, İlaç etkileşimleri)

Co-administration of probenecid with Cefazolin for Injection is not recommended. (Sefazolin etiketi, İlaç etkileşimleri)

Administration of cefotaxime in excess of 6 grams/day should be avoided in patients receiving probenecid (see CLINICAL PHARMACOLOGY, Drug Interactions ). (Sefotaksim etiketi, İlaç etkileşimleri)

Coadministration with probenecid increases systemic exposure to cefuroxime axetil and is therefore not recommended. (Sefuroksim etiketi, İlaç etkileşimleri)

TO REDUCE POSSIBLE NEPHROTOXICITY, INTRAVENOUS PREHYDRATION WITH NORMAL SALINE AND ADMINISTRATION OF PROBENECID MUST BE USED WITH EACH CIDOFOVIR INFUSION. (Sidofovir etiketi, Kutulu uyarı)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Probenesid ve kolşisin etiketi, Uyarılar)

In order to prevent gout flares when treatment with allopurinol tablets is initiated, concurrent prophylactic treatment with colchicine or an anti-inflammatory agent is recommended [ see Dosage and Administration (2.2) ]. (Allopurinol etiketi, Uyarılar ve önlemler)

Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (> 1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Drug Interactions Coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve. (Asiklovir etiketi, İlaç etkileşimleri)

Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (>1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ] . (Atorvastatin etiketi, Uyarılar ve önlemler)

Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised. (Azitromisin etiketi, İlaç etkileşimleri)

In patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors (e.g., probenecid) the recommended dosage should be reduced. (Barisitinib etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (Bromokriptin etiketi, İlaç etkileşimleri)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Probenesid ve kolşisin etiketi, Uyarılar)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Probenesid ve kolşisin etiketi, Uyarılar)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Probenesid ve kolşisin etiketi, Uyarılar)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; and hypotension with calcium channel blockers metabolized by CYP3A4 (for example, verapamil, amlodipine, diltiazem) (see PRECAUTIONS, Drug Interactions ). (Eritromisin etiketi, Uyarılar)

Lipid modifying doses (≥1 gram/day) of niacin, fibrates, colchicine, and grapefruit juice may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1) ] . (Ezetimib ve simvastatin etiketi, Uyarılar ve önlemler)

Probenecid: May increase penciclovir levels. (Famsiklovir etiketi, İlaç etkileşimleri)

In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

Consider whether the benefit of using colchicine concomitantly with fenofibrate outweighs the increased risk of myopathy [see Drug Interactions (7) ]. (Fenofibrat etiketi, Uyarılar ve önlemler)

Consider whether the benefit of using colchicine concomitantly with fenofibric acid delayed-release capsules outweighs the increased risk of myopathy [see Drug Interactions (7) ] . (Fenofibrik asit etiketi, Uyarılar ve önlemler)

When used concomitantly with fluvastatin sodium extended-release tablets, lipid modifying doses (≥ 1 g/day) of niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions ( 7.1 )] . (Fluvastatin etiketi, Uyarılar ve önlemler)

Fosamprenavir calcium/ritonavir and coadministration of colchicine: Treatment of gout flares: 0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour later. (Fosamprenavir etiketi, İlaç etkileşimleri)

Probenecid ↑Ganciclovir Ganciclovir for Injection dose may need to be reduced. (Gansiklovir etiketi, İlaç etkileşimleri)

(G) Colchicine Myopathy, including rhabdomyolysis, has been reported with chronic administration of colchicine at therapeutic doses. (Gemfibrozil etiketi, İlaç etkileşimleri)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Probenesid ve kolşisin etiketi, Uyarılar)

Probenecid Clinical Impact: When indomethacin is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased. (İndometazin etiketi, İlaç etkileşimleri)

Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudine, nevirapine, ritonavir, probenecid, saquinavir, and tenofovir) are co-administered with COMETRIQ [see Clinical Pharmacology ( 12.3 )] . (Kabozantinib etiketi, İlaç etkileşimleri)

In addition, ketamine and thiopental anesthesia were significantly prolonged in rats receiving probenecid. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057. (Levetirasetam etiketi, İlaç etkileşimleri)

However, these changes do not warrant dosage adjustment for Levofloxacin in 5% Dextrose Injection when probenecid or cimetidine is co-administered. (Levofloksasin etiketi, İlaç etkileşimleri)

Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (Lomitapid etiketi, İlaç etkileşimleri)

Colchicine: Cases of myopathy, including rhabdomyolysis, have been reported with lovastatin coadministered with colchicine, and caution should be exercised when prescribing lovastatin with colchicine (see PRECAUTIONS , Drug Interactions ). (Lovastatin etiketi, Uyarılar)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid increases plasma concentrations of methotrexate in both animals and humans. (Probenesid ve kolşisin etiketi, Uyarılar)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. (Naproksen etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Probenesid ve kolşisin etiketi, Uyarılar)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Probenesid ve kolşisin etiketi, Uyarılar)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Probenesid ve kolşisin etiketi, Uyarılar)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Probenesid ve kolşisin etiketi, Uyarılar)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

The following drugs when used concomitantly with LIVALO may also increase the risk of myopathy and rhabdomyolysis: lipid-modifying dosages of niacin (>1grams/day), fibrates, and colchicine [see Drug Interactions (7) ]. (Pitavastatin etiketi, Uyarılar ve önlemler)

The following drugs when used concomitantly with pravastatin sodium may also increase the risk of myopathy and rhabdomyolysis: niacin, fibrates, and colchicine [see Drug Interactions ( 7 )]. (Pravastatin etiketi, Uyarılar ve önlemler)

Concomitant use with probenecid and cotrimoxazole increases the concentration of rifampin which may increase the risk of rifampin toxicities. (Rifampisin etiketi, İlaç etkileşimleri)

Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions ( 7.1) ]. (Rosuvastatin etiketi, Uyarılar ve önlemler)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

…Immunosuppressives Other Drugs ciprofloxacin melphalan amphotericin B azapropazon cimetidine tacrolimus fibric acid derivatives (e.g., bezafibrate, fenofibrate) gentamicin ketoconazole colchicine ranitidine methotrexate tobramycin diclofenac trimethoprim with sulfamethoxazole naproxen vancomycin sulindac During the concomitant use of a drug that may exhibit additive… (Siklosporin etiketi, İlaç etkileşimleri)

Lipid modifying doses (≥1 gram/day) of niacin, fibrates, colchicine, and grapefruit juice may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1) ] . (Simvastatin etiketi, Uyarılar ve önlemler)

Decrease ciprofloxacin absorption, resulting in lower serum and urine levels Probenecid Use with caution (interferes with renal tubular secretion of ciprofloxacin and increases ciprofloxacin serum levels) Potentiation of ciprofloxacin toxicity may occur. (Siprofloksasin etiketi, İlaç etkileşimleri)

Probenecid : May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (Sodyum fenilbütirat etiketi, İlaç etkileşimleri)

Probenecid given concomitantly with sulindac had only a slight effect on plasma sulfide levels, while plasma levels of sulindac and sulfone were increased. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. (Sumatriptan ve naproksen etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Organic Anion Drugs Coadministration of organic anion drugs (e.g., probenecid) that undergo significant renal tubular secretion have the potential to reduce secretion of torsemide into the proximal tubule and thereby decreases the diuretic activity of torsemide. (Torasemid etiketi, İlaç etkileşimleri)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Probenesid ve kolşisin etiketi, Uyarılar)

Didanosine ↔ Ganciclovir ↑ Didanosine Patients should be closely monitored for didanosine toxicity (e.g., pancreatitis) Probenecid ↑ Ganciclovir Valganciclovir hydrochloride dose may need to be reduced. (Valgansiklovir etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin, and chloramphenicol). (Entakapon etiketi, Önlemler)

Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid Probenecid is a blocker of renal tubular secretion. (Gabapentin etiketi, İlaç etkileşimleri)

Probenecid : May affect renal excretion of metabolites of glycerol phenylbutyrate, including phenylacetylglutamine (PAGN) and PAA. (Gliserol fenilbütirat etiketi, İlaç etkileşimleri)

These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol). (Karbidopa, levodopa ve entakapon etiketi, İlaç etkileşimleri)

These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Uricosuric Drugs Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. (Nitrofurantoin etiketi, İlaç etkileşimleri)

Probenecid The concomitant use of probenecid with certain other quinolones has been reported to affect renal tubular secretion. (Ofloksasin etiketi, İlaç etkileşimleri)

Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

The uricosuric action of probenecid is also antagonized by pyrazinamide. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

…hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories–propoxyphene, aspirin, indomethacin,… (Prazosin etiketi, İlaç etkileşimleri)

Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Probenecid does not affect renal tubular transport of gentamicin. (Gentamisin etiketi, İlaç etkileşimleri)

Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir Combination Oral Contraceptives Clinical Impact Concomitant use with mycophenolate mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology ( 12.3 )], which may result in reduced combination oral contraceptive… (Mikofenolat etiketi, İlaç etkileşimleri)